Cyclacel Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 1.13
Market capitalization 10.12M
Operating cash flow -20.21M
ESG Scores unknown

Company description

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 554k -2.21M 30k 2.91M
Total Cashflows From Investing Activities -39k 28k -96k -27k
Net Borrowings
Total Cash From Financing Activities 429k 3.85M 29.5M 21.74M
Change To Operating Activities -327k 214k 124k -3.93M
Issuance Of Stock 630k 4.05M 25.99M 21.94M
Net Income -7.29M -7.83M -8.45M -18.89M
Change In Cash -6.41M -5.62M 21.52M 3.15M
Effect Of Exchange Rate -95k -48k 47k -17k
Total Cash From Operating Activities -6.7M -9.45M -7.93M -18.54M
Depreciation 29k 20k 20k 43k
Change To Account Receivables
Other Cashflows From Financing Activities -60k -60k -60k
Change To Netincome 331k 357k 337k 1.33M
Capital Expenditures -39k -10k -96k -27k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 4.61M 4.61M 4.61M 15.14M
Income Before Tax -8.62M -9.13M -9.68M -22.73M
Net Income -7.29M -7.83M -8.45M -18.89M
Selling General Administrative 5.37M 5.02M 5.88M 7.46M
Gross Profit -4.18M -4.66M -152k -338k
Ebit -9.55M -9.68M -10.64M -22.94M
Operating Income -9.55M -9.68M -10.64M -22.94M
Interest Expense
Income Tax Expense -1.34M -1.3M -1.24M -3.85M
Total Revenue 150k
Cost Of Revenue 4.33M 4.66M 152k 338k
Total Other Income ExpenseNet 923k 556k 955k 204k
Net Income From Continuing Ops -7.29M -7.83M -8.45M -18.89M
Net Income Applicable To Common Shares -7.49M -8.03M -12.42M -19.09M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 4.55M 3.61M 3.54M 5.32M
Total Stockholder Equity 15.27M 11.7M 33.26M 37.26M
Other Current Liabilities 363k 678k 866k 634k
Total Assets 19.82M 15.31M 36.8M 42.59M
Common Stock 12k 1k 6k 10k
Other Current Assets 236k 103k 66k 79k
Retained Earnings -349.8M -357.63M -366.07M -384.96M
Treasury Stock -760k -819k -746k -748k
Cash 17.5M 11.88M 33.41M 36.56M
Total Current Liabilities 4.45M 2.42M 2.49M 5.29M
Other Stockholder Equity -760k -819k -746k -748k
Property, Plant, and Equipment 36k 1.29M 1.33M 94k
Total Current Assets 19.79M 14.02M 35.47M 40.94M
Net Tangible Assets 15.27M 11.7M 33.26M 37.26M
Net Receivables 1.15M 1.33M 1.31M 3.73M
Accounts Payable 2.72M 890k 514k 2.12M


Insider Transactions

Here are the insider transactions of stock shares related to Cyclacel Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
BARKER SAMUEL LStock Award(Grant) at price 0.00 per share.D2022-06-14Director15.82k
HENNEY CHRISTOPHER SStock Award(Grant) at price 0.00 per share.D2022-06-14Director15.82k
WALKER KARIN LStock Award(Grant) at price 0.00 per share.D2022-06-14Director15.82k
SCHWARTZ BRIANStock Award(Grant) at price 0.00 per share.D2022-06-14Director15.82k
SEMS LLOYD MStock Award(Grant) at price 0.00 per share.D2022-06-14Director15.82k
SPIEGEL ROBERT JStock Award(Grant) at price 0.00 per share.D2022-06-14Director15.82k
FERGUSON KENNETH MStock Award(Grant) at price 0.00 per share.D2022-06-14Director27.73k
FERGUSON KENNETH MStock Award(Grant) at price 0.00 per share.D2022-06-14Director23.73k
BARKER SAMUEL LSale at price 3.57 per share.D2021-11-30Director12
ROMBOTIS SPIRO GEORGEPurchase at price 4.50 per share.D2021-11-18Chief Executive Officer4k
BARKER SAMUEL LPurchase at price 5.00 per share.D2021-08-24Director1k
BARKER SAMUEL LStock Award(Grant) at price 0.00 per share.D2021-06-15Director2.37k
HENNEY CHRISTOPHER SStock Award(Grant) at price 0.00 per share.D2021-06-15Director2.37k
HRADSKY GREGORY TStock Award(Grant) at price 0.00 per share.D2021-06-15Director2.37k
WALKER KARIN LStock Award(Grant) at price 0.00 per share.D2021-06-15Director3.56k
SCHWARTZ BRIANStock Award(Grant) at price 0.00 per share.D2021-06-15Director3.56k
SEMS LLOYD MStock Award(Grant) at price 0.00 per share.D2021-06-15Director2.37k
SPIEGEL ROBERT JStock Award(Grant) at price 0.00 per share.D2021-06-15Director2.37k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Cyclacel Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Cyclacel Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to Cyclacel Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Cyclacel Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Cyclacel Pharmaceuticals Inc:

Cyclacel Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -34.77% on the backtest period.

Performance at glance

Performance

-34.77 %

Latent gain

-602.85 $

Invested capital

1733.73 $

Annualized return

-8.48 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Cyclacel Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to Cyclacel Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Cyclacel Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on Cyclacel Pharmaceuticals Inc:

Cyclacel Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give -34.44% of return on Cyclacel Pharmaceuticals Inc. That represents -1555.35$ of latent gain with 4516.47$ of employed capital.
  • The second momentum investment strategy would give -31.36% of return on Cyclacel Pharmaceuticals Inc. That represents -1099.1$ of latent gain with 3504.7$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-34.44 %

Latent gain

-1555.35 $

Invested capital

4516.47 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-31.36 %

Latent gain

-1099.1 $

Invested capital

3504.7 $

Annualized return

-8.66 %

Momentum equity curve on Cyclacel Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to Cyclacel Pharmaceuticals Inc:

Cyclacel Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by Cyclacel Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cyclacel Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on Cyclacel Pharmaceuticals Inc since the beginning:

Cyclacel Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Cyclacel Pharmaceuticals Inc

Buy the dip entry openings on Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

The performance achieved by the robo-advisor on Cyclacel Pharmaceuticals Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Cyclacel Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Cyclacel Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Cyclacel Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to Cyclacel Pharmaceuticals Inc:

Cyclacel Pharmaceuticals Inc

Note: the dividends potentially given by Cyclacel Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Cyclacel Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Cyclacel Pharmaceuticals Inc:

Cyclacel Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Cyclacel Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to Cyclacel Pharmaceuticals Inc.

Equity curve comparison on Cyclacel Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Cyclacel Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc investment comparison

Performance comparison on Cyclacel Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -34.77% -602.85$ 1733.73$ -8.48%
Momentum 1 quarter -34.44% -1555.35$ 4516.47$ -8.92%
Momentum 2 quarters -31.36% -1099.1$ 3504.7$ -8.66%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-8.48 %

Momentum 1Q

-8.66 %

Momentum 2Q

-8.66 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Cyclacel Pharmaceuticals Inc:

Note: The algorithm computes the probability of correlation between Cyclacel Pharmaceuticals Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Cyclacel Pharmaceuticals Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Cyclacel Pharmaceuticals Inc
Country United States
City Berkeley Heights
Address 200 Connell Drive
Phone 908 517 7330
Website www.cyclacel.com
FullTime employees
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker CYCC
Market www.nasdaq.com

Cyclacel Pharmaceuticals Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown